Day: October 25, 2022

Posted on

La Fondation Bill & Melinda Gates annonce un soutien supplémentaire pour promouvoir la R&D locale. Appels à propositions

BRUXELLES, 25 octobre 2022 /PRNewswire/ — La Fondation Bill & Melinda Gates a annoncé aujourd’hui une série d’initiatives et un appel à propositions en vue de faire progresser l’innovation locale qui soutient les travaux de scientifiques et de chercheurs dans les économies en développement. L’annonce a été faite lors de la réunion annuelle de Grand Challenges plus tôt aujourd’hui.

La réunion de cette année se concentre sur les enseignements tirés de la pandémie de COVID-19, qui a mis en évidence la nécessité de plateformes de R&D à fort impact, de partenariats et de politiques qui comblent efficacement le fossé existant entre l’innovation et l’accès équitable. La réunion rapproche des chercheurs du monde entier pour partager leurs travaux, en apprendre davantage sur les avancées de pointe dans le domaine des soins de santé et permettre une collaboration avec d’autres chercheurs.

« L’équité en santé ne devrait pas uniquement être un énoncé de la raison pour laquelle nous faisons ce travail. Elle devrait guider la façon dont nous le réalisons », a déclaré Kedest Tesfagiorgis, directeur adjoint des Partenariats mondiaux et des grands défis à la Fondation Bill & Melinda Gates. « Lorsque nous soutenons l’innovation locale, nous maximisons l’impact en mettant en lumière différents types de connaissances et de perspectives. »

Dans le cadre de l’Appel mondial à l’action de Grand Challenges, une initiative sur 10 ans annoncée lors de la réunion de l’année dernière pour aider à s’assurer que les scientifiques et les institutions des pays à revenu faible et intermédiaire (PRFI) jouent un rôle central dans l’élaboration du programme mondial de R&D, deux nouvelles initiatives Grand Challenges ont été annoncée par la fondation :

  • La surveillance génomique des agents pathogènes et l’immunologie en Asie : Il s’agit d’une invitation à soumission par les chercheurs en Asie du Sud et du Sud-Est pour concevoir et piloter un programme de surveillance génomique ou de développer des capacités en immunologie et séquençage immunitaire du SRAS-CoV-2 afin d’éclairer la réponse épidémique. Un montant allant jusqu’à 300 000 $ par année pour une période maximale de deux ans seront disponibles pour chaque projet, avec un financement supplémentaire potentiel pour les projets qui mettent l’accent sur la recherche d’anticorps monoclonaux.
  • Le renforcement des capacités de modélisation des données pour l’égalité des sexes  : Il s’agit d’un appel à propositions lancé aux chercheurs de pays à revenu faible ou intermédiaire pour des projets visant à éliminer les disparités et les lacunes affectant les femmes et les filles dans le domaine de la santé. Cette initiative est axée sur des approches novatrices de modélisation pour faire progresser l’égalité des sexes. Chaque projet recevra jusqu’à 500 000 $ sur une période d’un à trois ans.

« Les sociétés mesurent ce qu’elles valorisent, et pour une grande partie de l’histoire, la société n’a pas valorisé les femmes. Cela signifie que nous essayons de relever des défis mondiaux en matière de santé et de développement sans disposer de toutes les informations nécessaires », a déclaré Anita Zaidi, présidente du département de l’Égalité des sexes à la Fondation Bill & Melinda Gates. « Il est grand temps de placer les femmes et les filles au centre de la modélisation des données qui guide nos solutions. »

En partenariat avec l’Initiative Chan Zuckerberg (CZI), la fondation accordera également des subventions aux chercheurs qui étudient et détectent les agents pathogènes émergents dans les PRFI. Les chercheurs recevront jusqu’à 200 000 $ chacun, pour une période maximale de deux ans, ainsi que le soutien opérationnel et une formation technique du Biohub Chan Zuckerberg  (CZ Biohub). Cet engagement de financement s’appuie sur un partenariat de 2018 entre la fondation, CZI et le CZ Biohub, qui se concentre sur le renforcement des capacités métagénomiques dans les PRFI par le biais d’une Initiative mondiale Grand Challenges.

La réunion annuelle de Grand Challenges 2022 à Bruxelles est organisée par Global Grand Challenges et la Commission européenne, et est coparrainée par Grands Défis Canada, USAID, Wellcome et la Fondation Bill & Melinda Gates.

L’événement de deux jours réunit des dizaines de leaders du paysage mondial de l’innovation en santé, ainsi que des dirigeants de la Fondation Gates, notamment Bill Gates (coprésident et administrateur), Anita Zaidi et Trevor Mundel (Président, Division de la santé mondiale). Les séances plénières seront publiées peu après la réunion sur le site grandchallenges.org/annual-meeting.

À propos de Grand Challenges

La Fondation Bill & Melinda Gates reconnaît que la résolution des défis les plus urgents en matière de santé et de développement mondiaux nécessite que davantage des esprits les plus brillants du monde y travaillent. La série d’initiatives Grand Challenges cherche à mobiliser des innovateurs du monde entier pour aider à résoudre ces défis. Les initiatives Grand Challenges sont unies par leur volonté de favoriser l’innovation, d’orienter la recherche là où elle aura le plus grand impact et d’aider ceux qui en ont le plus besoin. Pour en savoir plus, visitez le site grandchallenges.org.

À propos de la Fondation Bill & Melinda Gates

Guidée par la conviction que chaque vie a la même valeur, la Fondation Bill & Melinda Gates s’efforce d’aider toutes les personnes à mener une vie saine et productive. Dans les pays en développement, elle vise à améliorer la santé des populations et à leur donner la possibilité de ne plus souffrir de la faim et de l’extrême pauvreté. Aux États-Unis, elle vise à faire en sorte que toutes les personnes, en particulier celles qui ont le moins de ressources, aient accès aux opportunités dont elles ont besoin pour réussir à l’école et dans la vie. Basée à Seattle, Washington, la fondation est dirigée par son PDG Mark Suzman, sous la direction des coprésidents Bill Gates et Melinda French Gates et du Conseil d’administration.

Contact pour les médias : media@gatesfoundation.org

Posted on

IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development for Potential Outbreak Research and Response

Merck will provide the investigational vaccine based on a proven platform technology

NEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus (SUDV) vaccine candidate that IAVI is developing into clinical evaluation in response to the rapidly spreading outbreak of SUDV disease in Uganda.

Merck plans to produce and provide vials of candidate vaccine from existing investigational drug substance to IAVI to supplement IAVI’s ongoing SUDV vaccine development program. The investigational vaccine being produced is based on the same vesicular stomatitis virus (VSV) viral vector platform that is used in ERVEBO®, Merck’s highly efficacious, single-dose Zaire ebolavirus (EBOV) vaccine that has achieved regulatory approval by the U.S. FDA, the European Medicines Agency (EMA) and a number of regulatory authorities in Africa.

IAVI and Merck have been in discussions with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders regarding the potential production and supply of doses of investigational SUDV vaccine to help support the WHO’s efforts to conduct a clinical trial of vaccine candidates in Uganda, in partnership with the Government of Uganda.

Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “We are grateful to Merck for supplying the vaccine material, and we look forward to the opportunity to demonstrate vaccine effectiveness and safety so that we are prepared for future outbreaks of SUDV, as well as the SUDV outbreak in Uganda should it not be promptly contained by public health measures alone. Outbreak response is more effective at containing disease spread when countermeasures work quickly, and we are hopeful that this one-dose vaccine, which is likely to generate a rapid immune response, will be a critical part of Sudan virus containment efforts in the future.”

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Production schedules and quantities are still being defined. Based on the quantities of available bulk drug substance and current plans, Merck hopes to be able to deliver approximately 55,000 doses by the end of the year. IAVI is actively working to accelerate the manufacture of additional doses of IAVI’s VSV-SUDV vaccine should they be needed. The number of doses provided by Merck should be sufficient for conducting Phase I and efficacy studies as well as for public health response if the outbreak in Uganda continues or spreads and should the vaccine be shown to be safe and efficacious.

IAVI will act as developer and regulatory sponsor and will be responsible for all aspects of future development of the vaccine candidate.

No SUDV vaccines have been approved to date, and existing EBOV vaccines and treatments are not effective against SUDV. In the midst of the ongoing SUDV disease outbreak, ensuring that all promising vaccine candidates are evaluated for safety and efficacy could enable vaccine stockpiles to be established for use in future outbreaks.

Vesicular stomatitis virus is the vector that underpins ERVEBO® as well as IAVI’s portfolio of emerging infectious disease vaccine candidates. These include the SUDV vaccine candidate supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European & Developing Countries Clinical Trials Partnership (EDCTP); a Marburg virus vaccine candidate supported by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD) and BARDA; and an intranasal SARS-CoV-2 vaccine candidate supported by the Japan Ministry of Finance. VSV is a harmless animal virus; in the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – that stimulates an immune response.

IAVI holds a nonexclusive license to the VSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Funders who have made the development of IAVI’s VSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health (NIH); and through the generous support of the American people from the United States Agency for International Development (USAID).

Follow IAVI on Twitter, Facebook, LinkedIn, Instagram, and YouTube, and subscribe to our news updates.

IAVI Media Contact

Karie Youngdahl
Head, Global Communications
kyoungdahl@iavi.org
+1 332-282-2890

SOURCE: IAVI

Posted on

CDC Warns of Possible Surge of Flu Cases

After two years of low influenza case numbers during the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention warns of a possibly harsh flu season.

“The United States has experienced relatively little influenza activity since 2020, thanks, in part, to community mitigation measures used to control the spread of COVID-19, making the country ripe for a severe influenza season,” the CDC told VOA in an email.

According to the CDC, the flu is already spreading in parts of the South, with relatively high activity levels in Georgia and Texas, compared to the same period last year.

Although the influenza season in the U.S. is just beginning, “based on what we have seen in parts of the Southern Hemisphere, flu has the potential to hit us hard this year,” Dr. William Schaffner, medical director of the National Foundation for Infectious Diseases, said earlier this month.

Researchers often look to the Southern Hemisphere because its flu season hits first, usually from May to October, to foreshadow what will happen in the north, where flu season usually starts in October, peaks in December and can last through May.

Australia’s flu season hit that country two months earlier than usual and caused one of its worst seasons in recent years, with cases peaking about three times higher than average, according to the Australian government’s Department of Health and Aged Care. During Australia’s 2022 flu season, of the 225,332 laboratory-confirmed cases, there have been 308 influenza-associated deaths, the agency reported. In comparison, in 2020, of the 21,266 laboratory-confirmed cases, there were 37 influenza-associated deaths.

The flu hit younger people especially hard in Australia. Although COVID-19 has been relatively mild for younger people, experts caution that children may be at especially high risk this year. That’s because many children have not been exposed to the flu due to COVID-19 safety precautions, including the use of masks, remote learning and social distancing taken in recent years, leaving them without natural immunity.

Influenza A, which causes more serious illness than other strains of the virus, is more prevalent this year, according to CDC data. It also spreads about two to three times more rapidly than Influenza B, a less common type of influenza.

Although influenza symptoms are similar to those of a common flu, they are typically more intense and begin more abruptly. The symptoms include common cold symptoms, such as a cough or runny nose, but also range to symptoms such as a fever or body aches. Some people also experience vomiting or diarrhea, although this is more common in children than adults.

The CDC urges that Americans ages 6 months and older get a flu shot by the end of October. Experts say it’s the best way to be protected from the ailment.

“Over the past two years, we’ve seen some worrisome drops in flu vaccination coverage, especially in some groups of people who are at the highest risk of developing serious flu illness,” CDC Director Dr. Rochelle Walensky said during a news conference earlier this month.

Health officials fear fewer people will be vaccinated because of the anti-vaccine sentiment that increased during the COVID-19 pandemic. A survey by the National Foundation for Infectious Diseases found that fewer Americans said they will get the flu shot compared to years before.

The CDC told VOA News in an email that to help avoid the flu, “people should continue to practice the everyday preventive actions that we saw work so well during the pandemic like social distancing, frequent handwashing, staying home when you are sick, and covering coughs and sneezes.”

“With a potentially challenging flu season ahead, I urge everyone to protect themselves and their families from flu and its potentially serious complications,” Walensky said.

Source: Voice of America

Posted on

Google Agrees to Compliance Reforms to Prevent Search Warrant Data Loss

The U.S. Justice Department said Tuesday it had reached an agreement with Alphabet Inc’s Google resolving a dispute with the search engine giant over the loss of data responsive to a 2016 search warrant.

The government said it was a “first-of-its-kind resolution” that would result in Google reforming “its legal process compliance program to ensure timely and complete responses to legal process such as subpoenas and search warrants.”

“The department is committed to ensuring that electronic communications providers comply with court orders to protect and facilitate criminal investigations,” said Assistant Attorney General Kenneth Polite, who heads the Justice Department’s Criminal Division.

The settlement demonstrated the department’s “resolve in ensuring that technology companies, such as Google, provide prompt and complete responses to legal process to ensure public safety and bring offenders to justice,” he added.

Google said it had a “long track record of protecting our users” privacy, including pushing back against overbroad government demands for user data, and this agreement in no way changes our ability or our commitment to continue doing so.”

The company told a U.S. court it had spent more than $90 million “on additional resources, systems, and staffing to implement legal process compliance program improvements.”

The Justice Department said an independent compliance professional will be hired to serve as an outside third party related to Google’s compliance upgrades.

In 2016, the United States obtained a search warrant in California for data held at Google related to the investigation of the criminal cryptocurrency exchange BTC-e, the department said.

Later the U.S. Court of Appeals for the Second Circuit ruled search warrants issued under the Stored Communications Act (SCA) did not cover data stored outside of the United States.

In 2018, Congress clarified the SCA did cover U.S. providers that chose to store data overseas, but the government said that “in the intervening time, data responsive to the warrant was lost,” the Justice Department said.

Google will assemble reports and updates regarding the compliance program that will go to the government, the Google Compliance Steering Committee and Alphabet board committees.


Source: Voice of America

Posted on

 IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development for Potential Outbreak Research and Response

Merck will provide the investigational vaccine based on a proven platform technology

NEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus (SUDV) vaccine candidate that IAVI is developing into clinical evaluation in response to the rapidly spreading outbreak of SUDV disease in Uganda.

Merck plans to produce and provide vials of candidate vaccine from existing investigational drug substance to IAVI to supplement IAVI’s ongoing SUDV vaccine development program. The investigational vaccine being produced is based on the same vesicular stomatitis virus (VSV) viral vector platform that is used in ERVEBO®, Merck’s highly efficacious, single-dose Zaire ebolavirus (EBOV) vaccine that has achieved regulatory approval by the U.S. FDA, the European Medicines Agency (EMA) and a number of regulatory authorities in Africa.

IAVI and Merck have been in discussions with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders regarding the potential production and supply of doses of investigational SUDV vaccine to help support the WHO’s efforts to conduct a clinical trial of vaccine candidates in Uganda, in partnership with the Government of Uganda.

Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “We are grateful to Merck for supplying the vaccine material, and we look forward to the opportunity to demonstrate vaccine effectiveness and safety so that we are prepared for future outbreaks of SUDV, as well as the SUDV outbreak in Uganda should it not be promptly contained by public health measures alone. Outbreak response is more effective at containing disease spread when countermeasures work quickly, and we are hopeful that this one-dose vaccine, which is likely to generate a rapid immune response, will be a critical part of Sudan virus containment efforts in the future.”

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Production schedules and quantities are still being defined. Based on the quantities of available bulk drug substance and current plans, Merck hopes to be able to deliver approximately 55,000 doses by the end of the year. IAVI is actively working to accelerate the manufacture of additional doses of IAVI’s VSV-SUDV vaccine should they be needed. The number of doses provided by Merck should be sufficient for conducting Phase I and efficacy studies as well as for public health response if the outbreak in Uganda continues or spreads and should the vaccine be shown to be safe and efficacious.

IAVI will act as developer and regulatory sponsor and will be responsible for all aspects of future development of the vaccine candidate.

No SUDV vaccines have been approved to date, and existing EBOV vaccines and treatments are not effective against SUDV. In the midst of the ongoing SUDV disease outbreak, ensuring that all promising vaccine candidates are evaluated for safety and efficacy could enable vaccine stockpiles to be established for use in future outbreaks.

Vesicular stomatitis virus is the vector that underpins ERVEBO® as well as IAVI’s portfolio of emerging infectious disease vaccine candidates. These include the SUDV vaccine candidate supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European & Developing Countries Clinical Trials Partnership (EDCTP); a Marburg virus vaccine candidate supported by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD) and BARDA; and an intranasal SARS-CoV-2 vaccine candidate supported by the Japan Ministry of Finance. VSV is a harmless animal virus; in the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – that stimulates an immune response.

IAVI holds a nonexclusive license to the VSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Funders who have made the development of IAVI’s VSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health (NIH); and through the generous support of the American people from the United States Agency for International Development (USAID).

Follow IAVI on Twitter, Facebook, LinkedIn, Instagram, and YouTube, and subscribe to our news updates.

IAVI Media Contact

Karie Youngdahl
Head, Global Communications
kyoungdahl@iavi.org
+1 332-282-2890

SOURCE: IAVI

Posted on

La Plateforme de Yoga française Shiksha® lance son Application et son Réseau Social membre

PARIS , 25 octobre 2022 /PRNewswire/ — Shiksha s’adresse à tous les pratiquants, débutants ou confirmés, qui aspirent à une pratique plus régulière et moins contraignante du yoga. Shiksha leur permet d’améliorer leur pratique personnelle du yoga ou de développer leurs compétences pédagogiques, en qualité de Professeur de yoga.

L’application donne accès à des cours de yoga en ligne, accessibles à la demande ou en direct, pour toutes les personnes recherchant davantage de qualité, de liberté et de commodité dans la découverte ou dans l’approfondissement de sa pratique. Shiksha propose également de nombreuses ressources téléchargeables et MasterClass (e-learning) à destination des professionnels de l’enseignement. Grâce à l’application, les utilisateurs peuvent notamment télécharger les contenus sur leur appareil, les regarder en mode hors connexion et créer leurs propres playlists personnalisées. Les membres de la tribu peuvent échanger entre-eux grâce à un réseau social interne réservé aux membres, y publier leur propres contenus (photos, publications) et notifier instantanément d’autres membres, grâce aux notifications Push par @identifiant utilisateur.

Shiksha se distingue notamment par la qualité éditoriale et technique de ses programmes, présentés sous forme de séries thématiques ou de MasterClass, et réalisés avec des moyens de production professionnels. Shiksha se base sur la technologie de streaming leader du marché (identique à Netflix), afin de garantir une expérience fluide et sans artefacts, quelle que soit la nature de la connexion côté utilisateur. Les cours hebdomadaires diffusés en lives, via un flux HD 1080p, proposent ainsi une expérience immersive et de qualité broadcast.

Shiksha propose une formule découverte totalement gratuite, pour accéder à des séances de méditation hebdomadaires diffusées en direct tous les mercredis matins. Le catalogue de plus de 800 vidéos est quant à lui accessible au moyen d’un abonnement mensuel au tarif de 16,99€/mois. Une formule annuelle à 149,99€ permet de réaliser une économie équivalente à 4 mois d’abonnement, (soit 12,50€/mois). Les abonnements démarrent après une période de gratuité de 14 jours, pendant lesquels l’utilisateur peut librement résilier son abonnement. Les accès aux MasterClass et aux cours en direct sont également possibles par achat unitaire (sans abonnement). Le code SHIKSHA2022, valable pour tout premier abonnement mensuel souscrit via le site Web uniquement, offre 2 mois gratuits jusqu’au 31/12/2022.

Visitez notre site Web : https://shiksha.yoga

Téléchargez l’application mobile :

Contact: namaste@shiksha.yoga

Photo – https://mma.prnewswire.com/media/1926478/Shiksha_Yoga_App.jpg

Posted on

China in Translation: Exhibition of International Communication Achievements of China Books in the New Era formally kicks off

FRANKFURT, Germany, Oct. 25, 2022 /PRNewswire/ — China in Translation: Exhibition of International Communication Achievements of China Books in the New Era, 2022 formally opened at the Frankfurt Book Fair in Germany on October 19, 2022. Hosted by China National Publications Import and Export (Group) Co., Ltd.(CNPIEC), the five-day event includes a physical book fair and a broadcasting of media videos collection. The physical book fair presents a collection of more than 300 titles originally written in Chinese alongside their translated versions into more than 30 languages, including English, Russian and German, which covers a wide range of topics, such as Chinese economy, literature, history, art and some topics about contemporary China. The media collection displays videos featuring 20 internationally renowned scholars and experts elaborating on topics related to China, including Violeta Bulc, former European Commissioner for mobility and transport of European Commission and former Deputy Prime Minister of Slovenia and Stephan Petermann, advisor of Dutch Creative Industries Fund.

The featured exhibition, a brand project created by CNPIEC and displayed in an exhibit for the first time in 2019, comprehensively presents the publication and promotion of Chinese books in overseas markets from multiple perspectives based on China’s key achievements in the global publishing sector, with the aim of promoting exchanges and collaborations between Chinese and international publishing communities as well as facilitating communications between China and foreign cultures.